Literature DB >> 17990051

Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey.

Jaana Suvisaari1, Jonna Perälä, Samuli I Saarni, Tommi Härkänen, Sami Pirkola, Matti Joukamaa, Seppo Koskinen, Jouko Lönnqvist, Antti Reunanen.   

Abstract

Schizophrenia and other psychotic disorders are associated with increased risk of developing type 2 diabetes. However, previous studies are mainly based on clinical samples where the comorbidity may be stronger. We investigated in a general population survey the prevalence of type 2 diabetes in persons with psychotic disorders and in users of antipsychotic medication. The study was based on a nationally representative two-stage cluster sample of 8,028 persons aged 30 or over from Finland. Diagnostic assessment of psychotic disorders combined SCID-I interview and case note data. Prevalences of type 2 diabetes, adjusting for age and sex, were estimated by calculating predicted marginals. The prevalence estimate of type 2 diabetes was 22.0% among subjects with schizophrenia, 13.4% among subjects with other nonaffective psychosis and 6.1% in subjects without psychotic disorders. Only two subjects (3.4%) with affective psychosis had type 2 diabetes. Users of all types of antipsychotic medication had increased prevalence of type 2 diabetes. Our results suggest that type 2 diabetes is a major health concern among persons with schizophrenia and other nonaffective psychotic disorders and also in users of antipsychotic medication, but persons with affective psychosis in the general population may not have increased prevalence of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17990051     DOI: 10.1007/s00406-007-0762-y

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  44 in total

1.  FDA warns antipsychotic drugs may be risky for elderly.

Authors:  Bridget M Kuehn
Journal:  JAMA       Date:  2005-05-25       Impact factor: 56.272

2.  The increasing medical burden in bipolar disorder.

Authors:  David J Kupfer
Journal:  JAMA       Date:  2005-05-25       Impact factor: 56.272

3.  Diabetes mellitus in schizophrenic patients.

Authors:  S Mukherjee; P Decina; V Bocola; F Saraceni; P L Scapicchio
Journal:  Compr Psychiatry       Date:  1996 Jan-Feb       Impact factor: 3.735

4.  Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders.

Authors:  Dan Cohen; Ronald P Stolk; Diederick E Grobbee; Christine C Gispen-de Wied
Journal:  Diabetes Care       Date:  2006-04       Impact factor: 19.112

5.  Diabetes mellitus in patients with schizophrenia in Taiwan.

Authors:  Chi-Fa Hung; Ching-Kuan Wu; Pao-Yen Lin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2005-03-05       Impact factor: 5.067

Review 6.  Schizophrenia, antipsychotics and diabetes: Genetic aspects.

Authors:  F Bellivier
Journal:  Eur Psychiatry       Date:  2005-12       Impact factor: 5.361

7.  Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.

Authors:  Douglas L Leslie; Robert A Rosenheck
Journal:  Am J Psychiatry       Date:  2004-09       Impact factor: 18.112

Review 8.  Atypical antipsychotics and glucose dysregulation: a systematic review.

Authors:  Hua Jin; Jonathan M Meyer; Dilip V Jeste
Journal:  Schizophr Res       Date:  2004-12-01       Impact factor: 4.939

9.  Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.

Authors:  Martina C M Ryan; Patrick Collins; Jogin H Thakore
Journal:  Am J Psychiatry       Date:  2003-02       Impact factor: 18.112

10.  Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.

Authors:  Frank Gianfrancesco; Amy Grogg; Ramy Mahmoud; Ruey Hua Wang; Dennis Meletiche
Journal:  Clin Ther       Date:  2003-04       Impact factor: 3.393

View more
  18 in total

1.  Mobility limitations in persons with psychotic disorder: findings from a population-based survey.

Authors:  Satu Viertiö; Päivi Sainio; Seppo Koskinen; Jonna Perälä; Samuli I Saarni; Marja Sihvonen; Jouko Lönnqvist; Jaana Suvisaari
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-09-17       Impact factor: 4.328

2.  Cholesterol and triglycerides in antipsychotic-naive patients with nonaffective psychosis.

Authors:  Brian Kirkpatrick; Clemente Garcia-Rizo; Kun Tang; Emilio Fernandez-Egea; Miguel Bernardo
Journal:  Psychiatry Res       Date:  2010-06-23       Impact factor: 3.222

3.  The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey.

Authors:  M K Yazici; A E Anil Yağcioğlu; A Ertuğrul; N Eni; S Karahan; E Karaağaoğlu; S L Tokgözoğlu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-06-03       Impact factor: 5.270

4.  Diabetes is associated with lower global cognitive function in schizophrenia.

Authors:  Yoichiro Takayanagi; Nicola G Cascella; Akira Sawa; William W Eaton
Journal:  Schizophr Res       Date:  2012-09-29       Impact factor: 4.939

5.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

6.  The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations.

Authors:  K J Burghardt; R Pop-Busui; M J Bly; T B Grove; S F Taylor; V L Ellingrod
Journal:  Clin Transl Sci       Date:  2012-11-01       Impact factor: 4.689

7.  Five-year mortality of Finnish schizophrenia patients in the era of deinstitutionalization.

Authors:  Helena Rantanen; Anna-Maija Koivisto; Raimo K R Salokangas; Mika Helminen; Hannu Oja; Sami Pirkola; Kristian Wahlbeck; Matti Joukamaa
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-28       Impact factor: 4.328

Review 8.  Diabetes and Schizophrenia.

Authors:  Jaana Suvisaari; Jaakko Keinänen; Saana Eskelinen; Outi Mantere
Journal:  Curr Diab Rep       Date:  2016-02       Impact factor: 4.810

9.  Metabolome in schizophrenia and other psychotic disorders: a general population-based study.

Authors:  Matej Orešič; Jing Tang; Tuulikki Seppänen-Laakso; Ismo Mattila; Suoma E Saarni; Samuli I Saarni; Jouko Lönnqvist; Marko Sysi-Aho; Tuulia Hyötyläinen; Jonna Perälä; Jaana Suvisaari
Journal:  Genome Med       Date:  2011-03-23       Impact factor: 11.117

10.  Cardiometabolic management in severe mental illness requiring an atypical antipsychotic.

Authors:  Allison Schmitz; Melissa Rohrich; William Newman; Pamela Wolf
Journal:  Ment Health Clin       Date:  2018-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.